Italia markets open in 4 hours 20 minutes

Biotest Aktiengesellschaft (0N70.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
35,70+0,30 (+0,85%)
Alla chiusura: 4:19PM BST

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
49 61 03 801 0

Impiegati a tempo pieno1.928

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Michael RamrothChairman of the Management Board, CEO & CFO1,21MN/D1961
Dr. Georg FloßCOO & Member of the Board of Management1,05MN/DN/D
Dr. Monika ButtkereitHead of Investor RelationsN/DN/DN/D
Dr. Christina ErbHead of Corp. HRN/DN/DN/D
Dr. Katrin BernösterHead of the Project Management OrganisationN/DN/DN/D
Mr. Peter SeithHead of Quality OperationsN/DN/DN/D
Dr. Jörg SchüttrumpfHead of R&DN/DN/DN/D
Dr. Wolfgang MöllerHead of Devel. - Plasma ProteinN/DN/DN/D
Dr. Hermann KeuperSr. VP of ManufacturingN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.


Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.

Governance aziendale

L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.